[{"data":1,"prerenderedAt":28},["ShallowReactive",2],{"$fpDBAeDb_et5I33J6h2bTqGYqdYmajl5OhIYH3XjAiTg":3},{"card":4,"examId":6,"chapterTitle":25,"prev":26,"next":27},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":17,"lectureRef":17,"storyRef":17,"chapterSlug":18,"sectionCode":19,"sectionTitle":20,"clusterSlug":21,"term":17,"sequenceOrder":22,"regionWeight":17,"revisionMark":23,"isActive":24},"ch4-112","touhan","プソイドエフェドリン製剤について、解熱鎮痛薬としての効能を有する場合の販売数量上限は1包装あたり何日分か。",2,[10,11,12,13],"3日分","5日分","7日分","10日分","multiple_choice","プソイドエフェドリンは原則5日分ですが、解熱鎮痛薬としての効能を有する場合は7日分まで認められます。","成分ごとに「かぜ薬」「鼻炎用内服薬」「解熱鎮痛薬」のいずれの効能で7日分が認められるかが異なる点に注意が必要です。プソイドエフェドリンの場合は解熱鎮痛薬での例外、ブロモバレリル尿素はかぜ薬・鼻炎用内服薬での例外となります。",null,"chapter-4","4-II-2","リスク区分に応じた販売方法・特定販売","shitei-ranyou-boushi",112,"令和8年4月一部改訂",true,"第4章 薬事関係法規・制度","ch4-111","ch4-113",1784619074407]